American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

Robert A. Kyle, Gary C Yee, Mark R. Somerfield, Patrick J. Flynn, Susan Halabi, Sundar Jagannath, Robert Z. Orlowski, David G. Roodman, Patricia Twilde, Kenneth Anderson

Research output: Contribution to journalReview article

327 Citations (Scopus)

Abstract

Purpose: To update the recommendations for the use of bisphosphonates in the prevention and treatment of bone disease in multiple myeloma. The Update Committee expanded the guideline to include a discussion of osteonecrosis of the jaw (ONJ). Methods: For the 2007 update, an Update Committee composed of members from the full panel completed a review and analysis of data published since 2002. Searches of Medline and the Cochrane Collaboration Library databases were performed. Recommendations: For multiple myeloma patients who have, on plain radiograph(s) or imaging studies, lytic destruction of bone or spine compression fracture from osteopenia, intravenous pamidronate 90 mg delivered over at least 2 hours or zoledronic acid 4 mg delivered over at least 15 minutes every 3 to 4 weeks is recommended. Clodronate is an alternative bisphosphonate approved worldwide, except in the United States, for oral or intravenous administration. New dosing guidelines for patients with pre-existing renal impairment were added to the zoledronic acid package insert. Although no similar dosing guidelines are available for pamidronate, the Update Committee recommends that clinicians consider reducing the initial pamidronate dose in patients with pre-existing renal impairment. Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended in this setting. The Update Committee suggests that bisphosphonate treatment continue for a period of 2 years. At 2 years, physicians should seriously consider discontinuing bisphosphonates in patients with responsive or stable disease, but further use is at the discretion of the treating physician. The Update Committee also discusses measures regarding ONJ.

Original languageEnglish (US)
Pages (from-to)2464-2472
Number of pages9
JournalJournal of Clinical Oncology
Volume25
Issue number17
DOIs
StatePublished - Jun 10 2007

Fingerprint

pamidronate
zoledronic acid
Medical Oncology
Diphosphonates
Multiple Myeloma
Practice Guidelines
Osteonecrosis
Guidelines
Jaw
Kidney
Committee Membership
Clodronic Acid
Product Labeling
Physicians
Compression Fractures
Metabolic Bone Diseases
Bone Diseases
Intravenous Administration
Libraries
Oral Administration

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. / Kyle, Robert A.; Yee, Gary C; Somerfield, Mark R.; Flynn, Patrick J.; Halabi, Susan; Jagannath, Sundar; Orlowski, Robert Z.; Roodman, David G.; Twilde, Patricia; Anderson, Kenneth.

In: Journal of Clinical Oncology, Vol. 25, No. 17, 10.06.2007, p. 2464-2472.

Research output: Contribution to journalReview article

Kyle, RA, Yee, GC, Somerfield, MR, Flynn, PJ, Halabi, S, Jagannath, S, Orlowski, RZ, Roodman, DG, Twilde, P & Anderson, K 2007, 'American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma', Journal of Clinical Oncology, vol. 25, no. 17, pp. 2464-2472. https://doi.org/10.1200/JCO.2007.12.1269
Kyle, Robert A. ; Yee, Gary C ; Somerfield, Mark R. ; Flynn, Patrick J. ; Halabi, Susan ; Jagannath, Sundar ; Orlowski, Robert Z. ; Roodman, David G. ; Twilde, Patricia ; Anderson, Kenneth. / American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 17. pp. 2464-2472.
@article{f643079c66b7409f960300a27b864db5,
title = "American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma",
abstract = "Purpose: To update the recommendations for the use of bisphosphonates in the prevention and treatment of bone disease in multiple myeloma. The Update Committee expanded the guideline to include a discussion of osteonecrosis of the jaw (ONJ). Methods: For the 2007 update, an Update Committee composed of members from the full panel completed a review and analysis of data published since 2002. Searches of Medline and the Cochrane Collaboration Library databases were performed. Recommendations: For multiple myeloma patients who have, on plain radiograph(s) or imaging studies, lytic destruction of bone or spine compression fracture from osteopenia, intravenous pamidronate 90 mg delivered over at least 2 hours or zoledronic acid 4 mg delivered over at least 15 minutes every 3 to 4 weeks is recommended. Clodronate is an alternative bisphosphonate approved worldwide, except in the United States, for oral or intravenous administration. New dosing guidelines for patients with pre-existing renal impairment were added to the zoledronic acid package insert. Although no similar dosing guidelines are available for pamidronate, the Update Committee recommends that clinicians consider reducing the initial pamidronate dose in patients with pre-existing renal impairment. Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended in this setting. The Update Committee suggests that bisphosphonate treatment continue for a period of 2 years. At 2 years, physicians should seriously consider discontinuing bisphosphonates in patients with responsive or stable disease, but further use is at the discretion of the treating physician. The Update Committee also discusses measures regarding ONJ.",
author = "Kyle, {Robert A.} and Yee, {Gary C} and Somerfield, {Mark R.} and Flynn, {Patrick J.} and Susan Halabi and Sundar Jagannath and Orlowski, {Robert Z.} and Roodman, {David G.} and Patricia Twilde and Kenneth Anderson",
year = "2007",
month = "6",
day = "10",
doi = "10.1200/JCO.2007.12.1269",
language = "English (US)",
volume = "25",
pages = "2464--2472",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "17",

}

TY - JOUR

T1 - American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

AU - Kyle, Robert A.

AU - Yee, Gary C

AU - Somerfield, Mark R.

AU - Flynn, Patrick J.

AU - Halabi, Susan

AU - Jagannath, Sundar

AU - Orlowski, Robert Z.

AU - Roodman, David G.

AU - Twilde, Patricia

AU - Anderson, Kenneth

PY - 2007/6/10

Y1 - 2007/6/10

N2 - Purpose: To update the recommendations for the use of bisphosphonates in the prevention and treatment of bone disease in multiple myeloma. The Update Committee expanded the guideline to include a discussion of osteonecrosis of the jaw (ONJ). Methods: For the 2007 update, an Update Committee composed of members from the full panel completed a review and analysis of data published since 2002. Searches of Medline and the Cochrane Collaboration Library databases were performed. Recommendations: For multiple myeloma patients who have, on plain radiograph(s) or imaging studies, lytic destruction of bone or spine compression fracture from osteopenia, intravenous pamidronate 90 mg delivered over at least 2 hours or zoledronic acid 4 mg delivered over at least 15 minutes every 3 to 4 weeks is recommended. Clodronate is an alternative bisphosphonate approved worldwide, except in the United States, for oral or intravenous administration. New dosing guidelines for patients with pre-existing renal impairment were added to the zoledronic acid package insert. Although no similar dosing guidelines are available for pamidronate, the Update Committee recommends that clinicians consider reducing the initial pamidronate dose in patients with pre-existing renal impairment. Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended in this setting. The Update Committee suggests that bisphosphonate treatment continue for a period of 2 years. At 2 years, physicians should seriously consider discontinuing bisphosphonates in patients with responsive or stable disease, but further use is at the discretion of the treating physician. The Update Committee also discusses measures regarding ONJ.

AB - Purpose: To update the recommendations for the use of bisphosphonates in the prevention and treatment of bone disease in multiple myeloma. The Update Committee expanded the guideline to include a discussion of osteonecrosis of the jaw (ONJ). Methods: For the 2007 update, an Update Committee composed of members from the full panel completed a review and analysis of data published since 2002. Searches of Medline and the Cochrane Collaboration Library databases were performed. Recommendations: For multiple myeloma patients who have, on plain radiograph(s) or imaging studies, lytic destruction of bone or spine compression fracture from osteopenia, intravenous pamidronate 90 mg delivered over at least 2 hours or zoledronic acid 4 mg delivered over at least 15 minutes every 3 to 4 weeks is recommended. Clodronate is an alternative bisphosphonate approved worldwide, except in the United States, for oral or intravenous administration. New dosing guidelines for patients with pre-existing renal impairment were added to the zoledronic acid package insert. Although no similar dosing guidelines are available for pamidronate, the Update Committee recommends that clinicians consider reducing the initial pamidronate dose in patients with pre-existing renal impairment. Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended in this setting. The Update Committee suggests that bisphosphonate treatment continue for a period of 2 years. At 2 years, physicians should seriously consider discontinuing bisphosphonates in patients with responsive or stable disease, but further use is at the discretion of the treating physician. The Update Committee also discusses measures regarding ONJ.

UR - http://www.scopus.com/inward/record.url?scp=34347260332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347260332&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.12.1269

DO - 10.1200/JCO.2007.12.1269

M3 - Review article

VL - 25

SP - 2464

EP - 2472

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 17

ER -